Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp (TNXP) is a clinical-stage biopharmaceutical company developing innovative therapeutics for central nervous system disorders, immunology, and infectious diseases. This page provides timely updates on TNXP's clinical trials, regulatory milestones, and strategic initiatives.
Key resources for investors include press releases covering product development progress, partnership announcements, and financial reports. Our curated news collection helps track TNXP's pipeline candidates like TNX-102 SL for fibromyalgia and Tonmya™ for PTSD management.
Stay informed about developments in migraine therapeutics, rare disease research, and vaccine programs. Content categories include FDA communications, clinical trial results, intellectual property updates, and market expansion activities.
Bookmark this page for direct access to verified TNXP updates. Check regularly for new developments in biopharmaceutical innovation impacting patient care and treatment paradigms.
Tonix Pharmaceuticals (NASDAQ:TNXP) is developing TNX-102 SL, a non-opioid drug for fibromyalgia, addressing the urgent need for safer pain management options amid the opioid crisis. The company plans to submit a New Drug Application (NDA) in October 2024, with potential for Priority Review. TNX-102 SL targets disturbed sleep in fibromyalgia patients, offering a novel approach to pain management without addiction risks.
Simultaneously, Vertex Pharmaceuticals has filed an NDA for VX-458, a non-opioid acute pain treatment granted Priority Review by the FDA. These developments reflect a broader industry shift towards non-addictive painkillers, supported by government initiatives like the HEAL Initiative. With an estimated 100 million Americans affected by chronic pain, including 10 million with fibromyalgia, these new treatments could significantly impact pain management practices and help combat the opioid epidemic.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced its participation in the 'Endpoints' panel at the RECOVER Treating Long COVID (TLC) workshop hosted by the Foundation for the National Institutes of Health (FNIH) and National Institute of Allergy and Infectious Diseases (NIAID). CEO Dr. Seth Lederman shared insights from developing TNX-102 SL for fibromyalgia and Long COVID.
Dr. Lederman recommended validating Patient Global Impression of Change (PGIC) as a primary endpoint for Long COVID therapeutic trials, drawing parallels to the successful use of Progression-Free Survival in cancer drug development. Tonix expects to submit a New Drug Application (NDA) for TNX-102 SL in fibromyalgia to the FDA in October.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the issuance of U.S. Patent No. 12,097,183, covering the subcutaneous delivery of Zembrace® SymTouch® (sumatriptan succinate injection) for migraine treatment. The patent, expected to provide market exclusivity until 2036, claims the use of a pre-filled autoinjector for treating migraines via subcutaneous administration.
Tonix recently launched an educational campaign, "Does Your Migraine Pill Work Every Time?" to promote non-oral migraine medications. The company is also launching a new website, www.gpmigraine.com, to educate patients about gastroparesis and migraine, emphasizing how non-oral medicines can help manage migraines more effectively.
Tonix Pharmaceuticals presented data on TNX-102 SL for fibromyalgia at the PDDS 2024 conference. The presentations highlighted the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, a sublingual cyclobenzaprine HCl tablet. Key points include:
1. Patents based on TNX-102 SL's eutectic composition are expected to provide market exclusivity until at least 2034.
2. FDA New Drug Application (NDA) submission is on track for October 2024, with Fast Track designation granted.
3. The Phase 3 RESILIENT study demonstrated statistically significant improvement in the primary endpoint of fibromyalgia nociplastic pain and all six key secondary endpoints.
4. TNX-102 SL's formulation allows for efficient transmucosal absorption and targeting of disturbed sleep.
5. In vitro tests have been developed to support manufacturing processes and product uniformity.
Tonix Pharmaceuticals (Nasdaq: TNXP) has been issued U.S. Patent No. 12,090,139 by the United States Patent and Trademark Office for its Tosymra® (sumatriptan nasal spray) 10mg, indicated for the acute treatment of migraine in adults. The patent, titled 'Formulations Comprising Triptan Compounds', covers the pharmaceutical composition, method of treating migraine via intranasal administration, and intranasal delivery system for Tosymra®. Set to expire in 2030, this patent strengthens Tosymra®'s market position as a differentiated drug with a unique administration method. CEO Seth Lederman emphasized that this new patent enhances Tosymra®'s intellectual property protection and solidifies its market presence.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is developing TNX-801, a promising single-dose mpox vaccine candidate that aligns with the World Health Organization's (WHO) preferred target product profile. TNX-801 shows potential advantages over current FDA-approved vaccines Jynneos and ACAM2000, including better tolerability, single-dose protection, and suitability for immunocompromised individuals. The vaccine has demonstrated efficacy against the new, more lethal Clade I mpox strain in preclinical trials. TNX-801's lyophilized version can be stable at ambient temperatures, making it more accessible in regions with cold-chain infrastructure. Tonix has partnered with Bilthoven Biologics to scale up production, potentially enabling global distribution to address the urgent need for a safer, more effective mpox vaccine.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that its single-dose mpox vaccine candidate TNX-801 aligns with the World Health Organization's (WHO) newly issued preferred target product profile (TPP) for mpox vaccines. The WHO released its TPP criteria at the Mpox Research and Innovation Scientific Conference held August 29-30, 2024. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature.
TNX-801 has shown single dose protection against a lethal challenge of Clade I monkeypox virus in animal studies. It is designed for percutaneous administration using a bifurcated needle and is expected to have stability at ambient temperature, eliminating the need for ultra-cold storage. The vaccine may also be suitable for use in immunocompromised individuals.
Tonix recently announced a collaboration with Bilthoven Biologics to develop GMP manufacturing processes for its mpox vaccine. The WHO's declaration of mpox as a Public Health Emergency of International Concern (PHEIC) underscores the urgent need for new vaccines to control the outbreak.
Tonix Pharmaceuticals (Nasdaq: TNXP) has appointed Thomas Englese as Executive Vice President of Commercial Operations. Englese brings over 20 years of biopharmaceutical industry experience, specializing in commercial operations, sales, and marketing. This appointment comes as Tonix prepares to submit a New Drug Application (NDA) for TNX-102 SL for fibromyalgia in October 2024.
Englese's expertise includes launching and managing major brands through all stages of commercialization. His previous roles include Chief Commercial Officer at Tris Pharmaceuticals and Aziyo Biologics, and Senior Vice President at Mallinckrodt PLC. Tonix CEO Seth Lederman expressed confidence in Englese's ability to advance the fibromyalgia program and build out the company's commercial capabilities.
Tonix Pharmaceuticals (TNXP) presented data on TNX-801, a potential mpox vaccine, at the University of Alberta. TNX-801, based on synthetic horsepox, demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox. New data showed improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues even at high doses. TNX-801 offers advantages over existing vaccines, including single-dose protection, percutaneous administration, and potential for long-lived immunity. The vaccine has been selected by NIH's Project NextGen for clinical testing. Tonix is collaborating with Bilthoven Biologics to develop GMP manufacturing processes for TNX-801. The company also highlighted the potential of TNX-801 as a viral vector platform for other infectious diseases.
Tonix Pharmaceuticals (Nasdaq: TNXP) has launched a national awareness campaign at PAINWeek about the impact of gastroparesis on oral migraine medication absorption. The campaign, titled 'Does Your Migraine Pill Work Every Time?', aims to educate patients and healthcare providers about the benefits of non-oral migraine treatments like nasal sprays and injectables.
Gastroparesis, a condition that slows stomach emptying, can delay or block the absorption of oral medications, leading to inconsistent migraine relief. Non-oral treatments bypass the digestive system, potentially offering faster relief in as little as 10 minutes. Tonix is launching a disease education website, gpmigraine.com, and supporting a webinar on September 19, 2024, to further educate patients about gastroparesis and migraine management options.